March 2019 - Metastatic Breast Cancer Trial Talk

Month: March 2019

PD-L1 Biomarker for Immunotherapy

To qualify for Tecentriq®-based immunotherapy, the cancer must test positive for the PD-L1 protein. Learn what researchers have found about PD-L1 and other biomarkers to identify patients suited for immunotherapy.

Read More
PAST ARTICLES

2020

2019

2018

SEARCH OUR SITE

for past articles or specific information.